Population pharmacokinetic analysis of TQ-B3203 following intravenous administration of TQ-B3203 liposome injection in Chinese patients with advanced solid tumors

Background: TQ-B3203 is a novel topoisomerase I inhibitor currently in development for the treatment of advanced solid tumors. Great differences in pharmacokinetic characteristics were found among individuals according to the phase I clinical trial following intravenous administration of TQ-B3203 li...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoqing, Bo, Yunhai, Yin, Han, Liu, Xiaohong, Li, Xu, Yang, Fen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885713/
https://www.ncbi.nlm.nih.gov/pubmed/36726585
http://dx.doi.org/10.3389/fphar.2023.1102244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885713/
https://www.ncbi.nlm.nih.gov/pubmed/36726585
http://dx.doi.org/10.3389/fphar.2023.1102244

Ejemplares similares